These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34664194)

  • 21. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
    Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
    Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma.
    Tran BD; Li J; Ly N; Faggioni R; Roskos L
    Cancer Chemother Pharmacol; 2023 Feb; 91(2):179-189. PubMed ID: 36625894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
    McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
    Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
    Powles T; Burotto M; Escudier B; Apolo AB; Bourlon MT; Shah AY; Suárez C; Porta C; Barrios CH; Richardet M; Gurney H; Kessler ER; Tomita Y; Bedke J; George S; Scheffold C; Wang P; Fedorov V; Motzer RJ; Choueiri TK
    ESMO Open; 2024 May; 9(5):102994. PubMed ID: 38642472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies.
    Li S; Li J; Peng L; Li Y; Wan X
    Front Pharmacol; 2021; 12():718014. PubMed ID: 34566643
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
    Ding D; Hu H; Shi Y; She L; Yao L; Zhu Y; Zeng S; Shen L; Huang J
    Oncologist; 2021 Feb; 26(2):e290-e297. PubMed ID: 32918790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price.
    Kim H; Goodall S; Liew D
    J Med Econ; 2021; 24(1):893-899. PubMed ID: 34259119
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma.
    Liao W; Huang J; Hutton D; Zhu G; Wu Q; Wen F; Bai L; Li Q
    Liver Int; 2019 Dec; 39(12):2408-2416. PubMed ID: 31544330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.
    McGregor B; Mortazavi A; Cordes L; Salabao C; Vandlik S; Apolo AB
    Cancer Treat Rev; 2022 Feb; 103():102333. PubMed ID: 35033866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective.
    Yoo M; Nelson RE; Cutshall Z; Dougherty M; Kohli M
    JCO Oncol Pract; 2023 Mar; 19(3):e449-e456. PubMed ID: 36599117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the Efficacy and Safety of Nivolumab Plus Cabozantinib versus Sunitinib in the Treatment of Elderly Patients with Advanced Clear Cell Renal Cell Carcinoma.
    Liu Y; Meng Y; Li M; Dong Y
    Arch Esp Urol; 2024 Jun; 77(5):584-590. PubMed ID: 38982788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan.
    Chandler C; Burnett H; Schaible K; Senthil V; Kato M; Miura Y; Osawa T; Uemura H; Kuwabara H
    J Med Econ; 2023; 26(1):1009-1018. PubMed ID: 37505931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
    Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
    J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.
    Chen J; Hu G; Chen Z; Wan X; Tan C; Zeng X; Cheng Z
    Clin Drug Investig; 2019 Oct; 39(10):931-938. PubMed ID: 31250401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
    Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
    JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States.
    Sieg M; Hartmann M; Settmacher U; Arefian H
    BMC Gastroenterol; 2020 Apr; 20(1):120. PubMed ID: 32316925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy.
    Capri S; Porta C; Condorelli C; Premoli E; Khare A; Kalra M; Modi N; Ratto B
    J Med Econ; 2020 Dec; 23(12):1579-1587. PubMed ID: 33079593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
    Capri S; Porta C; Delea TE
    Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.